<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833948</url>
  </required_header>
  <id_info>
    <org_study_id>ECRI 006 - H-15016807</org_study_id>
    <nct_id>NCT02833948</nct_id>
  </id_info>
  <brief_title>Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)</brief_title>
  <acronym>GALILEO-4D</acronym>
  <official_title>Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECRI bv</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardialysis BV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ECRI bv</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aortic valve is located between the left ventricle and the aorta. Patients with
      symptomatic, severe aortic valve stenosis conventionally have it surgically replaced
      requiring direct access to the heart through the chest. Transcatheter aortic valve
      replacement (TAVR) is now a well-established alternative for treating severe aortic valve
      stenosis. Both types of intervention improve prognosis and alleviate symptoms.

      The optimal choice of blood thinning therapy after TAVR is unknown. It has been reported that
      leaflet thrombosis with reduced leaflet motion can occur and this phenomenon has been
      suggested to be potentially related with neurological events. In addition, the occurence of
      this phenomenon can be reduced with anticoagulation blood thinning therapy.

      The purpose of this study is to evaluate if anticoagulation compared to the usual double
      platelet inhibitor therapy after TAVR can reduce the risk of leaflet thrombosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Transcatheter aortic valve replacement (TAVR) has become an established
      therapeutic option for patients with symptomatic, severe aortic valve stenosis, who are
      ineligible or at high risk for conventional surgical aortic valve replacement (SAVR). It was
      recently reported that leaflet thickening and reduced leaflet motion, verified by
      four-dimensional computed tomography (4DCT), was not uncommon after both TAVR and SAVR. It
      has been emphasized that this phenomenon should be further investigated for its effect on
      clinical outcomes (e.g. stroke) and valve durability. As this valve leaflet thickening and
      reduced motion could be reversed by oral anticoagulant (OAC) treatment and was not observed
      in patients on chronic OAC therapy, it has been hypothesized that this phenomenon could be
      related to possible leaflet thrombosis or a &quot;thrombotic film&quot; on the leaflets.

      AIM: To evaluate whether a rivaroxaban-based strategy, following successful TAVR, compared to
      an antiplatelet-based strategy, is superior in reducing subclinical valve leaflet thickening
      and motion abnormalities - as detected by 4DCT-scan.

      POPULATION: All patients undergoing successful TAVR by ileofemoral or subclavian access with
      an approved TAVR device will be screened for eligibility. Included subjects must provide
      written informed consent. Inclusion and exclusion criteria are listed below.

      DESIGN: The GALILEO-4D trial will be conducted as a substudy of the multicenter, open-label,
      randomized, event-driven, active-controlled GALILEO trial. Patients will be 1:1 randomized to
      an antiplatelet-based strategy vs. rivaroxaban-based strategy - the randomization will adopt
      the same 1:1 randomization of the main GALILEO trial. In case the GALILEO-4D trial should
      still be continued after completion of the main GALILEO trial, this 1:1 randomization will be
      continued until inclusion of 150 patients in both treatment groups. In total, 300 patients
      will be randomized in the GALILEO-4D trial.

      INTERVENTION: Subjects in the GALILEO-4D substudy will receive the same intervention as in
      the main GALILEO study. In addition, a 4DCT-scan and echocardiography will be performed at 90
      days after randomization.

      END POINTS: The primary endpoint constitutes the rate of patients with at least one
      prosthetic leaflet with &gt; 50% motion reduction as assessed by cardiac 4DCT-scan (total N =
      300). The secondary endpoints are listed below.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with at least one prosthetic leaflet with &gt;50% motion reduction as assessed by cardiac 4DCT-scan</measure>
    <time_frame>3 months</time_frame>
    <description>Reduced systolic leaflet excursion is classified as: (I) normal, (II) mildly reduced (&lt;50%), (III) moderate to severely reduced (&gt;50%), and (IV) immobile. Reduced systolic leaflet excursion is considered significant when it is &gt; 50% or immobile. Quantitative assessment of leaflet motion is performed with a blood pool inversion volume rendered cine reconstruction throughout the cardiac cycle evaluating the bioprosthetic leaflets.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of prosthetic leaflets with &gt; 50% motion reduction as assessed by cardiac 4DCT-scan</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients with at least one prosthetic leaflet with thickening as assessed by cardiac 4DCT-scan</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of prosthetic leaflets with thickening as assessed by cardiac 4DCT-scan</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional NYHA class.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death, first thromboembolic event (DTE), and safety endpoints (see GALILEO trial) will be assessed in the main GALILEO study and analyzed in the GALILEO-4D substudy with regards to occurence of the leaflet abnormalities - as exploratory analysis.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic transvalvular mean pressure gradient (mmHg) as determined by transthoracic echocardiography.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective orifice area (cm^2) as determined by transthoracic echocardiography.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Valve Diseases</condition>
  <condition>Ventricular Outflow Obstruction</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>ASA + Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban + ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylicsalicylic acid</intervention_name>
    <description>Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)</description>
    <arm_group_label>ASA + Clopidogrel</arm_group_label>
    <arm_group_label>Rivaroxaban + ASA</arm_group_label>
    <other_name>Asprin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Drug: Clopidogrel 75 mg OD for first 90 days</description>
    <arm_group_label>ASA + Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Drug: Rivaroxaban (Xarelto):
10 mg OD (once-daily)</description>
    <arm_group_label>Rivaroxaban + ASA</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successful TAVR of a native aortic valve stenosis

          -  By iliofemoral or subclavian access

          -  With any approved/marketed TAVR device

          -  Written informed consent

        Exclusion Criteria:

          -  Atrial fibrillation (AF), current or previous, with an ongoing indication for oral
             anticoagulant treatment

          -  Any other indication for continued treatment with any oral anticoagulant

          -  Known bleeding diathesis (such as but not limited to platelet count ≤ 50,000/mm3 at
             screening, hemoglobin level &lt; 8.5 g/dL or &lt; 5.3 mmol/l, history of intracranial
             hemorrhage, or subdural hematoma)

          -  Any indication for dual antiplatelet therapy (DAPT) for more than three months after
             randomization (such as coronary, carotid, or peripheral stent implantation)

          -  Clinically overt stroke within the last three months

          -  Planned coronary or vascular intervention or major surgery

          -  Severe renal insufficiency (eGFR &lt; 30 mL/min/1.73 m2) or on dialysis, or post-TAVR
             unresolved acute kidney injury with renal dysfunction ≥ stage 2

          -  Moderate and severe hepatic impairment (Child-Pugh Class B or C) or any hepatic
             disease associated with coagulopathy

          -  Iodine contrast allergy or other condition that prohibits CT imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Søndergaard, MD;DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars Søndergaard, MD, DMSc</last_name>
    <phone>+45 35452018</phone>
    <email>lars.soendergaard.01@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ole De Backer, MD; PhD</last_name>
    <phone>+45-35457086</phone>
    <email>ole.debacker@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raj Makkar</last_name>
      <email>raj.makkar@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mount Sinai M.C</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>George Dangas</last_name>
      <email>george.dangas@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas, Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <zip>AB T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Welsh</last_name>
      <email>Robert.Welsh@albertahealthservices.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Providence Health Care</name>
      <address>
        <city>Vancouver</city>
        <zip>ON M1L 1W1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Webb</last_name>
      <email>webb@providencehealth.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aarhus university hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian J Therkelsen</last_name>
      <email>christian.juhl.terkelsen@clin.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Søndergaard, MD; DMSc</last_name>
      <phone>+45-35458693</phone>
      <email>Lars.Soendergaard.01@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <phone>+45-35457086</phone>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karsten Veien</last_name>
      <email>karsten.veien@rsyd.dk</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik GmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Won-Keun</last_name>
      <email>W.Kim@kerckhoff-klinik.de</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charité- Universitätsmedizin Berlin - Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verena Stangl</last_name>
      <email>verena.stangl@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jörg Kempfert</last_name>
      <email>kempfert@dhzb.de</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helge Möllmann</last_name>
      <email>moellmann@me.com</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlange</city>
        <zip>91012</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Arnold</last_name>
      <email>martin.arnold@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norbert Frey</last_name>
      <email>Norbert.Frey@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medicin Herzzentrum Lahr/Baden</name>
      <address>
        <city>Lahr</city>
        <zip>77933</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eberhard ulz Schulz</last_name>
      <email>Eberhard.Schulz@unimedizin-mainz.de</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig - Universitätsklinik</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Axel Linke</last_name>
      <email>Axel.Linke@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Hengstenberg</last_name>
      <email>christian.hengstenberg@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robbert de Winter</last_name>
      <email>r.j.dewinter@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Amphia Zienkenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4818</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Willem Dewilde, DMSc</last_name>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Erasmus M.C</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas M Van Mieghem</last_name>
      <email>n.vanmieghem@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Gotberg</last_name>
      <email>matthias.gotberg@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Ruck</last_name>
      <email>andreas.ruck@karolinska.se</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raban Jeger</last_name>
      <email>Raban.Jeger@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Windecker</last_name>
      <email>stephan.windecker@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Ole De Backer</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, De Backer O, Asch FM, Ruiz CE, Olsen NT, Trento A, Friedman J, Berman D, Cheng W, Kashif M, Jelnin V, Kliger CA, Guo H, Pichard AD, Weissman NJ, Kapadia S, Manasse E, Bhatt DL, Leon MB, Søndergaard L. Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med. 2015 Nov 19;373(21):2015-24. doi: 10.1056/NEJMoa1509233. Epub 2015 Oct 5.</citation>
    <PMID>26436963</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Valve Disease</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>TAVR</keyword>
  <keyword>Valve Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Ventricular Outflow Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

